(REPL) Replimune - Ratings and Ratios
RP1, RP2, RP3, Oncolytic, Immunotherapies
REPL EPS (Earnings per Share)
REPL Revenue
Description: REPL Replimune
Replimune Group Inc is a clinical-stage biotechnology company that is revolutionizing the field of oncology through its innovative oncolytic immunotherapies. By harnessing the power of the immune system, the companys proprietary product candidates aim to combat cancer in a more effective and targeted manner. With a robust pipeline of promising candidates, including RP1, RP2, and RP3, Replimune is poised to make a significant impact in the treatment of various solid tumors.
The companys lead product candidate, RP1, is a genetically engineered version of the herpes simplex virus that is designed to selectively replicate in cancer cells, inducing a potent anti-tumor immune response. RP2 and RP3 build upon this concept, incorporating additional immune-activating proteins to further enhance the bodys natural defenses against cancer. With its cutting-edge technology and promising early-stage results, Replimune is an attractive prospect for investors seeking exposure to the rapidly evolving biotechnology sector.
From a technical analysis perspective, Replimunes stock price has been trending near its 20-day simple moving average (SMA) of $9.46, indicating a potential consolidation phase. The stocks relative strength index (RSI) is not provided, but the average true range (ATR) of 0.77 suggests moderate volatility. Given the current price of $9.27, a potential breakout above the SMA20 or a decline below the SMA50 of $8.75 could signal a significant directional move. With the 52-week high and low range being $14.93 and $6.92, respectively, there is a considerable scope for price movement.
Combining the technical and fundamental data, a forecast for Replimunes stock price can be derived. The companys market capitalization stands at $714.59M, with a negative return on equity (RoE) of -57.98, indicating significant investment in research and development. As RP1, RP2, and RP3 progress through clinical trials, a successful outcome could lead to a substantial increase in the stock price. Assuming a successful trial outcome and subsequent commercialization, a potential price target could be in the range of $15-$20, representing a 60-100% increase from current levels. However, this is contingent upon the companys ability to execute its clinical development plans and navigate the complex regulatory landscape.
It is essential to note that investing in a clinical-stage biotechnology company like Replimune carries inherent risks, including the uncertainty of clinical trial outcomes and regulatory approvals. As such, a thorough evaluation of the companys prospects and risks is crucial before making any investment decisions.
Additional Sources for REPL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
REPL Stock Overview
Market Cap in USD | 725m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2018-07-20 |
REPL Stock Ratings
Growth Rating | -61.1 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | 21.8 |
Analysts | 4.38 of 5 |
Fair Price Momentum | 7.69 USD |
Fair Price DCF | - |
REPL Dividends
Currently no dividends paidREPL Growth Ratios
Growth Correlation 3m | 59.1% |
Growth Correlation 12m | -27.2% |
Growth Correlation 5y | -84.4% |
CAGR 5y | -15.87% |
CAGR/Max DD 5y | -0.18 |
Sharpe Ratio 12m | -0.05 |
Alpha | -11.23 |
Beta | 1.986 |
Volatility | 66.39% |
Current Volume | 1288.3k |
Average Volume 20d | 1229.9k |
Stop Loss | 8.7 (-6.9%) |
As of July 09, 2025, the stock is trading at USD 9.34 with a total of 1,288,331 shares traded.
Over the past week, the price has changed by +2.08%, over one month by -8.25%, over three months by +30.81% and over the past year by +10.66%.
No, based on ValueRay´s Analyses, Replimune (NASDAQ:REPL) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -61.09 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of REPL is around 7.69 USD . This means that REPL is currently overvalued and has a potential downside of -17.67%.
Replimune has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy REPL.
- Strong Buy: 3
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, REPL Replimune will be worth about 9.2 in July 2026. The stock is currently trading at 9.34. This means that the stock has a potential downside of -1.18%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 21.9 | 134.3% |
Analysts Target Price | 21.9 | 134.3% |
ValueRay Target Price | 9.2 | -1.2% |